Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $204,084.96 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Myrtle Potter sold 1,556 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $204,084.96. Following the completion of the sale, the director directly owned 20,971 shares in the company, valued at $2,750,556.36. This represents a 6.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Performance

Shares of GH traded up $2.00 during midday trading on Tuesday, hitting $130.83. 1,931,570 shares of the stock traded hands, compared to its average volume of 2,130,785. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $135.00. The business’s 50 day moving average price is $108.07 and its two-hundred day moving average price is $103.04. The firm has a market capitalization of $17.35 billion, a PE ratio of -38.59 and a beta of 1.61.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in GH. Vanguard Group Inc. boosted its stake in Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after buying an additional 435,232 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. The Goldman Sachs Group initiated coverage on Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Guggenheim lowered Guardant Health from a “buy” rating to a “buy” rating in a report on Thursday, May 28th. TD Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. Finally, Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.